Till Balla

Till Balla

Auto-generated profile, based on publicly available information

Till Balla

Mechanisms of Protein Biogenesis, Max Planck Institute of Biochemistry, Martinsried, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in Science
Verified
Journal Article
Closed access
DFDomenico Di Fraia
Domenico Di Fraia
AMAntonio Marino
Antonio Marino
JLJae Ho Lee
Jae Ho Lee
ESErika Kelmer Sacramento
Erika Kelmer Sacramento
MBMario Baumgart
Mario Baumgart
AOAlessandro Ori
Alessandro Ori
Aging is a major risk factor for neurodegeneration and is characterized by diverse cellular and molecular hallmarks. To understand the origin of these hallmarks, we studied the effects of aging on the transcriptome, translatome, and proteome in the brain of short-lived killifish. We identified a cascade of events in which aberrant translation pausing led to altered abundance of proteins independently of transcriptional regulation. In particular, aging caused increased ribosome stalling and widespread depletion of proteins enriched in basic amino acids. These findings uncover a potential vulnerable point in the aging brain’s biology—the biogenesis of basic DNA and RNA binding proteins. This vulnerability may represent a unifying principle that connects various aging hallmarks, encompassing genome integrity, proteostasis, and the biosynthesis of macromolecules.

29 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
JBJose D. Barrera-Paez
Jose D. Barrera-Paez
SBSandra R. Bacman
Sandra R. Bacman
TBTill Balla
Till Balla
DBDerek Van Booven
Derek Van Booven
DGDurga P. Gannamedi
Durga P. Gannamedi
CMCarlos T Moraes
Carlos T Moraes
Primary mitochondrial disorders are most often caused by deleterious mutations in the mitochondrial DNA (mtDNA). Here, we used a mitochondrial DddA-derived cytosine base editor (DdCBE) to introduce a compensatory edit in a mouse model that carries the pathological mutation in the mitochondrial transfer RNA (tRNA) alanine (mt-tRNA Ala ) gene. Because the original m.5024C→T mutation (G→A in the mt-tRNA Ala ) destabilizes the mt-tRNA Ala aminoacyl stem, we designed a compensatory m.5081G→A edit (C→T in the mt-tRNA Ala ) that could restore the secondary structure of the tRNA Ala aminoacyl stem. For this, the DdCBE gene construct was initially tested in an m.5024C→T mutant cell line. The reduced mt-tRNA Ala amounts in these cells were increased after editing up to 78% of the mtDNA. Then, DdCBE was packaged in recombinant adeno-associated virus 9 (AAV9) and intravenously administered by retro-orbital injections into mice. Expression of the transduced DdCBE was observed in the heart and skeletal muscle. Total mt-tRNA Ala amounts were restored in heart and muscle by the m.5081G→A edit in a dose-dependent manner. Lactate amounts, which were increased in the heart, were also decreased in treated mice. However, the highest dose tested of AAV9-DdCBE also induced severe adverse effects in vivo because of the extensive mtDNA off-target editing that it generated. These results show that although DdCBE is a promising gene therapy tool for mitochondrial disorders, the doses of the therapeutic constructs must be carefully monitored to avoid deleterious off-target editing.